Livforsakringsbolaget Skandia Omsesidigt Cuts Position in Johnson & Johnson $JNJ

Key Points

• Livforsakringsbolaget Skandia Omsesidigt sharply cut its Johnson & Johnson stake by 91.4% in the fourth quarter, reducing holdings to 16,706 shares worth about $3.46 million.
• Several other large institutional investors also adjusted positions in J&J, including Norges Bank opening a new stake and Vanguard, Amundi, and Marshall Wace increasing their holdings. Overall, institutional investors own 69.55% of the company.
• Analysts remain broadly positive on the stock, with multiple firms raising price targets and J&J carrying a Moderate Buy consensus rating. The shares were trading up 2.3% at $228.32, while the company also reported a quarterly earnings beat and raised its dividend to $1.34 per share.

Livforsakringsbolaget Skandia Omsesidigt lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 91.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 16,706 shares of the company's stock after selling 178,561 shares during the period. Livforsakringsbolaget Skandia Omsesidigt's holdings in Johnson & Johnson were worth $3,457,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of JNJ. Norges Bank purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $6,924,523,000. Vanguard Group Inc. increased its stake in shares of Johnson & Johnson by 1.6% in the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company's stock valued at $49,740,362,000 after purchasing an additional 3,731,074 shares in the last quarter. Capital International Investors increased its stake in shares of Johnson & Johnson by 545.6% in the 3rd quarter. Capital International Investors now owns 3,865,050 shares of the company's stock valued at $716,657,000 after purchasing an additional 3,266,354 shares in the last quarter. Amundi increased its stake in shares of Johnson & Johnson by 19.3% in the 3rd quarter. Amundi now owns 13,354,936 shares of the company's stock valued at $2,512,719,000 after purchasing an additional 2,163,838 shares in the last quarter. Finally, Marshall Wace LLP increased its stake in shares of Johnson & Johnson by 126.3% in the 3rd quarter. Marshall Wace LLP now owns 3,584,162 shares of the company's stock valued at $664,575,000 after purchasing an additional 2,000,609 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on JNJ shares. The Goldman Sachs Group lifted their price target on Johnson & Johnson from $265.00 to $275.00 and gave the company a "buy" rating in a research note on Wednesday, April 15th. Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a report on Saturday, February 14th. Royal Bank Of Canada restated an "outperform" rating and set a $265.00 target price on shares of Johnson & Johnson in a report on Wednesday, April 15th. Argus upped their price objective on Johnson & Johnson from $240.00 to $275.00 and gave the company a "buy" rating in a report on Thursday, April 16th. Finally, Citigroup upped their price objective on Johnson & Johnson from $274.00 to $285.00 and gave the company a "buy" rating in a report on Tuesday, April 7th. Twenty investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $253.04.

Johnson & Johnson Trading Up 2.3%

NYSE JNJ opened at $228.32 on Friday. The firm's fifty day moving average price is $232.12 and its 200 day moving average price is $225.92. Johnson & Johnson has a 12 month low of $149.04 and a 12 month high of $251.71. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The company has a market capitalization of $549.63 billion, a price-to-earnings ratio of 26.40, a price-to-earnings-growth ratio of 2.19 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping the consensus estimate of $2.68 by $0.02. The firm had revenue of $24.06 billion for the quarter, compared to analyst estimates of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. Johnson & Johnson's revenue for the quarter was up 9.9% compared to the same quarter last year. During the same period last year, the business earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, sell-side analysts expect that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be issued a dividend of $1.34 per share. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, May 26th. Johnson & Johnson's payout ratio is presently 61.97%.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson presented multiple favorable ASCO 2026 data readouts, including practice-changing prostate cancer results for apalutamide and encouraging oncology/myeloma updates that support its specialty drug growth narrative. ASCO 2026 Data Underscore Johnson & Johnson’s Expanding Specialty Drug Story
• Positive Sentiment: Nipocalimab showed sustained lupus disease control in Phase 2 JASMINE data, with stronger responses in autoantibody-positive patients, bolstering J&J’s autoimmune pipeline and the case for future commercialization. Johnson & Johnson late-breaking results show nipocalimab significantly reduced systemic lupus erythematosus disease activity in a Phase 2 study
• Positive Sentiment: New Sjögren’s disease data further reinforced nipocalimab’s potential, showing greater clinical response in patients with higher autoantibody and IgG levels, which may indicate a meaningful treatment effect in more severe cases. Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögren's disease
• Neutral Sentiment: Newsweek named Johnson & Johnson among the World’s Greenest Companies 2026, a positive reputation item but not a major immediate earnings driver. Goldman Sachs, Johnson & Johnson, MetLife Named Among Newsweek’s World’s Greenest Companies 2026

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.